Fisetin
description1
description2
Basic information
Product Name: Fisetin
IUPAC Name: 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one
CAS No.: 345909-34-4
Molecular Formula: C₁₅H₁₀O₆
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
Yellow needle crystals |
Melting Point |
330°C (decomposition) |
Solubility |
0.01 mg/mL in water; soluble in DMSO (50 mg/mL) |
logP |
1.5 (amphiphilic) |
pKa |
6.7 (7-OH), 9.8 (4'-OH) |
Stability |
Light-sensitive; oxidizes under alkaline conditions |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Fisetin (CAS: 345909-34-4) |
98% by HPLC |
Loss on drying |
≤6.0% |
Residue on ignition |
≤5% |
Natural Source
Multi-Target Action
High Bioavailability
1.Molecular Target Network
2. Pharmacokinetics
Absorption
5% oral bioavailability (↑to 60% with nanoformulations).
Distribution
Brain/plasma ratio=0.6:1 (limited BBB penetration).
Metabolism
Hepatic UGT1A1-mediated glucuronidation (inactivation).
Excretion
Primarily fecal (85% clearance in 72h).
Clinical Applications
Indications & Protocols
Condition |
Regimen |
Evidence |
Aging Intervention |
100 mg/day ×6 months |
↑15% telomere length* |
Mild Cognitive Impairment |
20 mg bid (Phase II) |
↑2 MMSE points |
Diabetes Management |
150 mg/day |
↓0.5% HbA1c |
*Randomized controlled trial (n=120)
Special Populations
Hepatic Impairment: Reduce dose 50% (Child-Pugh B).
Pregnancy: Avoid high doses (embryotoxicity in animals).
Dosage and Administration
Formulations
Dietary Supplements: 50 mg/capsule (phospholipid complex).
Nanoformulations: 10 mg/mL (60% bioavailability).
Injection: 5 mg/mL (research use).
Dosing Guidelines
Use |
Dose |
Duration |
Anti-Aging |
50–100 mg/day |
Long-term |
Neuroprotection |
20–40 mg bid |
6–12 months |
Cancer Adjunct |
200 mg/day + chemo |
Clinical trials |
Safety Evaluation
Adverse Reactions
System |
Incidence |
Manifestations |
Gastrointestinal |
8% |
Mild diarrhea |
Hypersensitivity |
0.3% |
Rash |
Hepatic |
<1% |
Reversible ALT↑ |
Contraindications & Interactions
Absolute CI:
Flavonoid allergy.
Pregnancy (theoretical teratogenicity).
Cautions:CYP3A4 substrates (e.g., statins): May ↑50% plasma concentration.
Research Progress Green max
Novel Formulations
Nanostructured Lipid Carriers: ↑5× BBB penetration.
Prodrug Design: Palmitate ester improves bioavailability to 80%.
New Indications
Post-COVID Syndrome: Inhibits cytokine storm (↓60% IL-6).
Parkinson’s Disease: Protects dopaminergic neurons (↑40% TH⁺ cells in MPTP models).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.